These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26948676)

  • 21. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrodysplasia ossificans progressiva with minor unilateral hallux anomaly in a sporadic case from Northern Tanzania with the common ACVR1c.617G>A mutation.
    Saleh M; Commandeur J; Bocciardi R; Kinabo G; Hamel B
    Pan Afr Med J; 2015; 22():299. PubMed ID: 26966495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
    Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
    Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.
    Nakahara Y; Katagiri T; Ogata N; Haga N
    Am J Med Genet A; 2014 Jan; 164A(1):220-4. PubMed ID: 24259422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
    Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
    Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cytokines in bone diseases. BMP signaling and fibrodysplasia ossificans progressiva].
    Katagiri T; Kamizono J; Nakashima Y; Kitoh H; Susami T; Haga N
    Clin Calcium; 2010 Oct; 20(10):1510-7. PubMed ID: 20890033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease.
    Akyuz G; Gencer-Atalay K; Ata P
    Curr Opin Pediatr; 2019 Dec; 31(6):716-722. PubMed ID: 31693578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
    Katagiri T; Tsukamoto S; Kuratani M
    Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACVR1 Function in Health and Disease.
    Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
    Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
    [No Abstract]   [Full Text] [Related]  

  • 31. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrodysplasia Ossificans Progressiva: A Case Report with Pseudo-Ankylosis of the Temporomandibular Joint.
    Chaisrisawadisuk S; Oliver KJ; Constantine S; Azzopardi J; Anderson PJ; Moore MH
    Cleft Palate Craniofac J; 2024 May; 61(5):897-900. PubMed ID: 36536588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.
    Yamamoto R; Matsushita M; Kitoh H; Masuda A; Ito M; Katagiri T; Kawai T; Ishiguro N; Ohno K
    J Bone Miner Metab; 2013 Jan; 31(1):26-33. PubMed ID: 23011467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].
    Katagiri T
    Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exoneration of NF-kappaB dysregulation in fibrodysplasia ossificans progressiva.
    Ahn J; Feldman G; Terry L; Shore EM; Kaplan FS
    Clin Orthop Relat Res; 2003 Jan; (406):205-13. PubMed ID: 12579020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.
    de Gorter DJ; Jankipersadsing V; Ten Dijke P
    Curr Pharm Des; 2012; 18(27):4087-92. PubMed ID: 22630080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva.
    Nikishina IP; Arsenyeva SV; Matkava VG; Arefieva AN; Kaleda MI; Smirnov AV; Blank LM; Kostik MM
    Pediatr Rheumatol Online J; 2023 Aug; 21(1):92. PubMed ID: 37644581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.